immunotherapy

Kineta Announces Restructuring and Exploration of Strategic Alternatives

SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of…

5 months ago

Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting

Preclinical Research on Full-Thickness Cutaneous Wound Healing KNOXVILLE, TN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or…

5 months ago

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio…

5 months ago

Umoja Biopharma Announces Appointment of Britton Russell as Chief Financial Officer

Britton Russell Britton Russell, Chief Financial Officer, Umoja Biopharma SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., (Umoja),…

5 months ago

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today…

5 months ago

Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE)…

5 months ago

Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research

Conference In Dublin, Ireland on February 27 - 29, 2024Focuses on How to Bring Basic Science Discoveries to the Clinic…

5 months ago

ABVC’s New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars

FREMONT, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing…

5 months ago

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE…

5 months ago